What is Summit Therapeutics PLC (SMMT) stock price today?

Summit Therapeutics PLC (SMMT) currently trades at $18.08 per share. The stock has a market capitalization of $13.85B and a P/E ratio of —x.

Is SMMT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Summit Therapeutics PLC has a Smart Value Score of 20/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -6.05.

Is Summit Therapeutics PLC financially healthy?

Summit Therapeutics PLC's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -6.05 places it in the distress.

SMMT

Summit Therapeutics PLC

NASDAQ: SMMT · HEALTHCARE · BIOTECHNOLOGY

$18.08

+5.42% today

Updated 2026-05-08

Market cap

$13.85B

P/E ratio

—

P/S ratio

3,891.31x

EPS (TTM)

$-1.59

Dividend yield

—

52W range

$14 – $31

Volume

3.6M

Market cap

$13.85B

P/E ratio

—

P/S ratio

3,891.31x

EPS (TTM)

$-1.59

Dividend yield

—

52W range

$14 – $31

Volume

3.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

5.3

Quality

C+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-6.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target

$30.39

+68.09%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy11 Buy4 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -6.05 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-92.93M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$583190.00	$0.00	$0.00	$0.00	$0.00
Net income	$-65.17M	$-482.37M	$-176.77M	$-1.08B	$-189.42M
EPS	—	—	—	—	$-1.59
Free cash flow	$-34.41M	$-60.85M	$-113.67M	$-240.15M	$-92.93M
Profit margin	-11,174.75%	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-01-08	ANAND, BHASKAR	Buy	30,000	—
2026-01-02	ZANGANEH, MAHKAM	Buy	11,232	$8.76
2026-01-02	XIA, YU	Buy	35,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SMMT	$13.85B	20	3.7	3.0	5.0	5.3	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-38.45%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-20.52%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+42.20%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Summit Therapeutics PLC trades at $18.08. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -6.05, it sits in the distress.

Frequently asked questions

What is Summit Therapeutics PLC's stock price?

Summit Therapeutics PLC (SMMT) trades at $18.08.

Is Summit Therapeutics PLC overvalued?

Smart Value Score 20/100 (Grade F, Strong Sell).

What is the price target of Summit Therapeutics PLC (SMMT)?

The analyst target price is $30.39, representing +68.1% upside from the current price of $18.08.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-6.05 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio3,891.31x

ROE-270.90%

Beta-1.26

50D MA$18.45

200D MA$19.57

Shares out0.78B

Float0.13B

Short ratio—

Avg volume3.6M

Performance

1 week+12.19%

1 month-8.08%

3 months+20.61%

YTD+3.37%

1 year—

3 years—

5 years—

Compare

SMMT vs LLY →SMMT vs JNJ →SMMT vs ABBV →Stock screener →